ALK and cancer: The development of targeted cancer therapies has led to improved results in the metastatic setting for patients with lung adenocarcinomas which bear oncogenic driver alterations, such as epidermal growth factor receptor (EGFR) and re-arranged anaplastic lymphoma kinase (ALK) [4].